Abivax (ABVX) Non-Current Debt (2021 - 2026)

Abivax's Non-Current Debt history runs 6 years deep, the most recent figure standing at $38.8 million for Q1 2026.

• On a quarterly basis, Non-Current Debt rose 51.2% year-over-year to $38.8 million in Q1 2026; TTM through Mar 2026 was $38.8 million, a 51.2% increase from a year earlier, with the FY2025 full-year figure at $35.8 million, down 52.06% from the prior year.
• Non-Current Debt rose to $38.8 million in Q1 2026 per ABVX's latest filing, from $35.8 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $73.8 million in Q4 2024 and bottomed at $3.5 million in Q4 2023.
• The 5-year median for Non-Current Debt is $29.5 million (2025), against an average of $32.6 million.
• Across the five-year window, Non-Current Debt slumped 78.82% in 2023 and jumped 2002.93% in 2024, its largest moves.
• Year by year, Non-Current Debt stood at $16.6 million in 2022, then slumped by 78.82% to $3.5 million in 2023, then soared by 2002.93% to $73.8 million in 2024, then plunged by 51.44% to $35.8 million in 2025, then climbed by 8.15% to $38.8 million in 2026.
• Per Business Quant, the three latest ABVX Non-Current Debt figures stand at $38.8 million (Q1 2026), $35.8 million (Q4 2025), and $29.5 million (Q3 2025).